Render Target: STATIC
Render Timestamp:
9/18/2026, 5:53:35 AM EDT
9/18/2026, 9:53:35 AM UTC
Commit: 916faa3125cd7e5a4910ff1f822b1dee8ea9bfe0
Cell Signaling Technology Logo - Extra Large
1% for the planet logo

Mouse Immune Cell Marker Guide

Access the full library of downloadable pathway diagrams, along with recommended products for each signaling pathway.

Neutrophils F4/8 0 me d and Ly-6G + Mouse Immune Cell Marker Guide αβ T Cells CD3 + γδ T Cells CD4 and CD8 and CD3 + and γδ TCR + NK Cells NK 1.1 + or NKp46 + or NKG2D + and CD 3 Cytotoxic Granzyme + or Perforin + Activated Plasmacytoid Dendritic Cells (pDCs) Conventional Dendritic Cells (cDCs) CD 1 1c + and MHCI I + Granulocytes Macrophages F4/8 0 high Monocytes CD 1 4 + and F4/8 0 –/ low Plasma Cells BCMA + or CD 1 38 + Siglec-H + and CD3 1 7 + CD8α + Resident DCs CD8α + CD103 + Migratory DCs CD 1 03 + M2-like CD163 + or CD206 + or Arginase + B Cells CD 1 9 + Naïve IgD + and CD2 7 SwitchedMemory Ig D and CD27 + Unswitched IgD + and CD27 + Activated CD83 + Cell Type Class CD45 + Myeloid Cells CD11b + Lymphoid Cells NKT Cells CD3 + and NK 1.1 + + positiv e/ high expression negativ e/ low expression Functional State Markers Key Myeloid-Derived Suppressor Cells (MDSCs) Leukocytes Type II NKT Th9 PU.1 + and IL-9 + Tfh Bcl-6 + and CXCR5 + and IL-21 + Th22 AHR + and IL-22 + Helper T Cells (Th) CD4 + Cytotoxic T Cells CD8 + Th1 T-Bet + and IFNγ + Th2 GATA-3 + and IL-4 + Th17 RORγt + and IL- 1 7 + Treg FoxP3 + and CD25 + Activated CD69 + or CD25 + Central Memory IL7R α + and CD44 + and CD62L + Cytotoxic Granzyme + or Perforin + Effector CD44 + and CD62L Effector Memory IL7R α + and CD44 + or CD62L 2 Terminally Exhausted Tox/Tox2 + and PD - 1 high and TIGIT + Naïve CD4 4 and CD62L + Progenitor Exhausted TCF1/TCF7 + and PD - 1 high and TIM-3 high Subtypes CD69 + Mast Cells FcεR 1 α + and CD 1 1 7/c-Ki t + and CD2 3 + Eosinophils CD 1 93 + and F4/8 0 me d and Siglec-F + Monocytic (M) MDSCs Ly-6C + and Ly-6G and Arginase + Polymorph­onuclear (PMN) MDSCs Ly-6 C low and Ly-6G + and Arginase + cDC 1 s (excel at cross- presentation) XCR1 + or CLEC9A + M1-like CD86 + or CD80 + or iNOS + Type I NKT (iNKT) TCR Vα14-Jα 1 8 + Langerin + Langerhans Cells (LCs) Activated CD83 + MregDC LAMP3 + Basophils FcεR1α + and CD 1 1 7 /c-Ki t cDC2s CD 1 1b + or SIRPα + rev. 05/6/25

2026 © Cell Signaling Technology. All Rights Reserved.

The overall structure of the murine immune system is comparable to that of humans, consisting of both innate and adaptive components, and its efficacy is regulated in cancer. Importantly, mouse models have contributed substantially to our understanding of cancer biology, including the validation of cancer genes, the discovery of tumor biomarkers, and the assessment of investigational therapeutics. As in humans, mouse immune cells modulate tumor growth and suppression, driven by a complex network of cytokines, chemokines, and growth factors. Described below are the various populations of murine immune cells.

Mouse T cells are characterized by CD3 expression and are subdivided into CD4+ helper and CD8+ cytotoxic groups. T cell activation increases expression of CD69 and CD25, which are frequently used as markers of activation. CD8+ cytotoxic cells release serine proteases (granzyme) and pore-forming cytolytic proteins (perforin) to lyse target cancer cells, while CD4+ helper cells coordinate the immune response through secretion of various cytokines. As in humans, exhausted murine T cells express some combination of PD-1, TIM-3, and LAG-3; although, these molecules can also be expressed upon T cell activation. Naïve, memory, and effector T cells in mice can be distinguished through expression of CD62L, IL7Ra, and CD44. Multiple cytokine-producing subsets of CD4+ cells are characterized by expression of transcription factors, such as T-bet for antitumor Th1 cells and FoxP3/CD25 for protumor Treg.

Murine dendritic cells (DCs) present antigen to CD4+ and CD8+ T cells. Like human DCs, mouse cells are divided into plasmacytoid and conventional subclasses. Plasmacytoid DCs co-express Siglec-H and CD317 and produce type I IFNγ, while conventional DCs are characterized by expression of CD11c and MHCII. DCs that excel in cross-presentation to CD8+ T cells can be identified by expression of XCR1 or CLEC9A.

In mice, as in humans, apoptotic tumor cells can be discarded by macrophages, which express an adhesion G-protein-coupled receptor known as F4/80. Murine macrophage polarization also occurs, with M1-like cells identified by expression of CD86, CD80, or iNOS and M2-like cells identified by expression of CD163, CD206, or arginase. Expression of functional iNOS and its mRNA induction by IFNγ have been well-established in mice.

Natural killer (NK) cells of the murine innate immune system recognize and kill cancer cells via a combination of activating and inhibitory receptors that allows NK cells to kill cancer cells without harming the host. They can be identified by expression of NKG2D, NK1.1, or NKp46 in combination with a lack of CD3 expression. NK cells also produce immunoregulatory cytokines. Murine NK cell homeostasis and development have strongly been attributed to the SH-2-containing phosphatase SHIP1.

Lastly, murine myeloid-derived suppressor cells (MDSCs) express high levels of CD11b, arginase, and the granulocytic marker GR1, which is itself composed of the membrane proteins Ly6C and Ly6G. In mice, MDSCs have been found in tumors as well as in bone marrow, blood, spleen, liver, and lung. They are broadly categorized into monocytic (CD11b+ Ly6G- Ly6Chi) and polymophonuclear (CD11b+ Ly6G+ Ly6Clo) groups, the latter being the predominant population in most cancers. However, distinguishing peripheral mononuclear cells from neutrophils remains challenging and is an area of ongoing investigation.

Selected Reviews:

We would like to thank Kate Fitzgerald, Ph.D., UMass Medical School, Courtney Betts, Ph.D. Oregon Health and Science University, and Shadmehr (Shawn) Demehri, M.D., Ph.D.Massachusetts General Hospital Cancer Center, Harvard Medical School for reviewing this diagram.

created March 2019